vs
Humacyte, Inc.（HUMA）与Arcadia Biosciences, Inc.（RKDA）财务数据对比。点击上方公司名可切换其他公司
Arcadia Biosciences, Inc.的季度营收约是Humacyte, Inc.的1.9倍（$901.0K vs $467.0K）
Humacyte是一家临床阶段生物技术企业，专注于开发和商业化通用可植入的现成生物工程人体组织及治疗产品，核心业务覆盖血管护理、创伤治疗、再生医学等领域，为全球患者及医疗合作伙伴提供创新解决方案。
阿卡迪亚生物科学是一家美国上市农业生物技术企业，总部位于加利福尼亚州戴维斯，专注于开发可提升作物品质与产量的作物性状改良技术，该公司部分股权归道德指南针公司所有。
HUMA vs RKDA — 直观对比
营收规模更大
RKDA
是对方的1.9倍
$467.0K
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $467.0K | $901.0K |
| 净利润 | — | $-1.3M |
| 毛利率 | -1844.8% | 21.4% |
| 营业利润率 | -6603.0% | -152.8% |
| 净利率 | — | -148.3% |
| 营收同比 | — | -25.8% |
| 净利润同比 | — | 67.1% |
| 每股收益（稀释后） | $-0.19 | $-0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HUMARKDA
| Q4 25 | $467.0K | $901.0K | ||
| Q3 25 | $753.0K | $1.3M | ||
| Q2 25 | $301.0K | $1.5M | ||
| Q1 25 | $517.0K | $1.2M | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | $0 | $1.5M | ||
| Q2 24 | $0 | $1.3M | ||
| Q1 24 | $0 | $987.0K |
净利润HUMARKDA
| Q4 25 | — | $-1.3M | ||
| Q3 25 | $-17.5M | $856.0K | ||
| Q2 25 | $-37.7M | $-4.5M | ||
| Q1 25 | $39.1M | $2.6M | ||
| Q4 24 | — | $-4.1M | ||
| Q3 24 | $-39.2M | $-1.6M | ||
| Q2 24 | $-56.7M | $1.1M | ||
| Q1 24 | $-31.9M | $-2.4M |
毛利率HUMARKDA
| Q4 25 | -1844.8% | 21.4% | ||
| Q3 25 | 65.5% | 32.1% | ||
| Q2 25 | 29.2% | 43.4% | ||
| Q1 25 | 71.6% | 43.2% | ||
| Q4 24 | — | 31.9% | ||
| Q3 24 | — | 32.9% | ||
| Q2 24 | — | 51.5% | ||
| Q1 24 | — | 52.3% |
营业利润率HUMARKDA
| Q4 25 | -6603.0% | -152.8% | ||
| Q3 25 | -3239.0% | -88.5% | ||
| Q2 25 | -9876.1% | -34.4% | ||
| Q1 25 | -4484.3% | 44.2% | ||
| Q4 24 | — | -187.7% | ||
| Q3 24 | — | -114.5% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -160.9% |
净利率HUMARKDA
| Q4 25 | — | -148.3% | ||
| Q3 25 | -2325.4% | 65.7% | ||
| Q2 25 | -12511.0% | -306.4% | ||
| Q1 25 | 7570.4% | 216.6% | ||
| Q4 24 | — | -334.5% | ||
| Q3 24 | — | -104.9% | ||
| Q2 24 | — | 81.2% | ||
| Q1 24 | — | -245.5% |
每股收益（稀释后）HUMARKDA
| Q4 25 | $-0.19 | $-0.97 | ||
| Q3 25 | $-0.11 | $0.62 | ||
| Q2 25 | $-0.24 | $-3.26 | ||
| Q1 25 | $0.28 | $1.90 | ||
| Q4 24 | — | $-2.99 | ||
| Q3 24 | $-0.33 | $-1.18 | ||
| Q2 24 | $-0.48 | $0.78 | ||
| Q1 24 | $-0.29 | $-1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $50.5M | $4.6M |
| 总债务越低越好 | $35.4M | — |
| 股东权益账面价值 | $3.1M | $4.1M |
| 总资产 | $116.4M | $6.5M |
| 负债/权益比越低杠杆越低 | 11.40× | — |
8季度趋势，按日历期对齐
现金及短期投资HUMARKDA
| Q4 25 | $50.5M | $4.6M | ||
| Q3 25 | $19.5M | $5.9M | ||
| Q2 25 | $38.0M | $4.4M | ||
| Q1 25 | $62.8M | $3.2M | ||
| Q4 24 | — | $4.2M | ||
| Q3 24 | $20.6M | $6.6M | ||
| Q2 24 | $93.6M | $8.1M | ||
| Q1 24 | $115.5M | $8.5M |
总债务HUMARKDA
| Q4 25 | $35.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益HUMARKDA
| Q4 25 | $3.1M | $4.1M | ||
| Q3 25 | $-4.8M | $5.4M | ||
| Q2 25 | $4.1M | $4.5M | ||
| Q1 25 | $36.0M | $8.9M | ||
| Q4 24 | — | $6.2M | ||
| Q3 24 | $-63.7M | $10.3M | ||
| Q2 24 | $-28.3M | $11.7M | ||
| Q1 24 | $26.2M | $10.6M |
总资产HUMARKDA
| Q4 25 | $116.4M | $6.5M | ||
| Q3 25 | $91.5M | $8.6M | ||
| Q2 25 | $138.8M | $7.8M | ||
| Q1 25 | $162.6M | $13.0M | ||
| Q4 24 | — | $13.5M | ||
| Q3 24 | $114.8M | $15.2M | ||
| Q2 24 | $138.3M | $17.4M | ||
| Q1 24 | $161.5M | $16.0M |
负债/权益比HUMARKDA
| Q4 25 | 11.40× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-26.1M | $-861.0K |
| 自由现金流经营现金流 - 资本支出 | $-26.2M | — |
| 自由现金流率自由现金流/营收 | -5602.4% | — |
| 资本支出强度资本支出/营收 | 8.4% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-105.9M | — |
8季度趋势，按日历期对齐
经营现金流HUMARKDA
| Q4 25 | $-26.1M | $-861.0K | ||
| Q3 25 | $-23.9M | $-257.0K | ||
| Q2 25 | $-26.4M | $-2.0M | ||
| Q1 25 | $-28.6M | $-1.6M | ||
| Q4 24 | — | $-2.2M | ||
| Q3 24 | $-22.9M | $-1.8M | ||
| Q2 24 | $-21.3M | $-2.5M | ||
| Q1 24 | $-27.3M | $-3.2M |
自由现金流HUMARKDA
| Q4 25 | $-26.2M | — | ||
| Q3 25 | $-24.0M | — | ||
| Q2 25 | $-27.0M | — | ||
| Q1 25 | $-28.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-23.8M | — | ||
| Q2 24 | $-21.5M | $-2.5M | ||
| Q1 24 | $-27.7M | $-3.2M |
自由现金流率HUMARKDA
| Q4 25 | -5602.4% | — | ||
| Q3 25 | -3181.0% | — | ||
| Q2 25 | -8963.8% | — | ||
| Q1 25 | -5576.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -188.3% | ||
| Q1 24 | — | -326.5% |
资本支出强度HUMARKDA
| Q4 25 | 8.4% | 0.0% | ||
| Q3 25 | 6.5% | 0.0% | ||
| Q2 25 | 188.7% | 0.0% | ||
| Q1 25 | 44.1% | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 1.3% |
现金转化率HUMARKDA
| Q4 25 | — | — | ||
| Q3 25 | — | -0.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.73× | -0.61× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.31× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
